
|Videos|January 29, 2014
The Design and Results of TRINOVA-1
Author(s)Bradley J. Monk, MD
Bradley J. Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the TRINOVA-1 trial.
Advertisement
Clinical Pearls
Bradley J. Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the TRINOVA-1 trial.
- The TRINOVA-1 trial studied trebananib plus paclitaxel versus placebo plus paclitaxel in 919 patients who had recurrent ovarian cancer and up to three prior lines of therapy
- Trebananib plus weekly paclitaxel improved the hazard ratio for progression by 0.66
- The combination also improved response rate and the survival data, although not yet mature, showed a hazard ratio of 0.86
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
2
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
3
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
4
BI-1808 Plus Pembrolizumab Yield Antitumor Activity in Recurrent Ovarian Cancer
5



















